Related Experiment Video

Updated: Jul 4, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Primary pulmonary rhabdomyosarcoma in a 5-month-old boy: a case report

Henry L Chang1, Andrew E Rosenberg, Alison M Friedmann

  • 1Division of Pediatric Surgery, Department of Surgery, Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA.

Journal of Pediatric Hematology/Oncology
|June 6, 2008
PubMed

Insights

Pediatric primary pulmonary rhabdomyosarcoma (RMS) is rare. This case report details a 5-month-old treated for local recurrence, highlighting the youngest patient documented with this condition.

Area of Science:

  • Pediatric Oncology
  • Thoracic Surgery
  • Medical Imaging

Background:

  • Primary pulmonary rhabdomyosarcoma (RMS) is an exceptionally rare malignancy in children.
  • Early diagnosis and treatment are crucial for improving outcomes in pediatric cancers.

Observation:

  • A 5-month-old boy presented with symptoms initially diagnosed as pneumonia.
  • Diagnostic imaging confirmed primary pulmonary rhabdomyosarcoma, necessitating surgical resection.
  • The patient experienced local recurrence after initial chemotherapy, requiring further surgical intervention.

Findings:

  • The patient, the youngest reported with pulmonary RMS, underwent multiple thoracotomies for resection.
  • Current treatment includes local radiotherapy and a salvage chemotherapy regimen.
  • The long-term prognosis and impact of the patient's young age remain undetermined.

Implications:

  • This case underscores the importance of considering rare diagnoses in pediatric patients with persistent respiratory symptoms.
  • Further research is needed to understand the prognostic factors and optimize treatment strategies for pediatric pulmonary RMS.
  • This case contributes valuable data on the youngest patient diagnosed with this rare tumor, informing future clinical management.

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...